Abstract
Dear Editor,
I write to bring an attention to a rare disease, pseudomyxoma peritonei (PMP), which was first described by Werth in 1884, yet it remains an orphan disease with limited awareness (1). The incidence of PMP is one to two patients/per million in a year that might be due to misdiagnosis (2).
PMP typically arises from a ruptured mucinous tumour, usually originating from the appendix, stomach, gall bladder, small and large intestine, fallopian tubes, ovaries, pancreas and lung, and mucin accumulates inside the peritoneal cavity and is called ‘jelly belly’ (1). PMP is histopathologically classified into four subtypes, based on present of tumour cells, the amount of mucin and the aggressiveness level, which are low grade, high grade, high grade with signet ring cells and acellular mucin (2).
Keywords
References
- Bevan KE, Mohamed F, Moran BJ. Pseudomyxoma peritonei. World J Gastrointest Oncol 2010;2(1):44-50. [CrossRef] google scholar
- Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, Gonzâlez-Moreno S, et al. A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. Am J Surg Pathol 2016;40(1):14-26. [CrossRef] google scholar
- Shringi S Jr, Agrawal AK, Gadkari P. A Review of Pseudomyxoma Peritonei: Insights Into Diagnosis, Management, and Prognosis. Cureus 2024;16(5):e61244. [CrossRef] google scholar
- Kusamura S, Barretta F, Yonemura Y, Sugarbaker PH, Moran BJ, Levine EA, et al. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. JAMA Surg 2021;156(3):e206363. [CrossRef] google scholar
- Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012;30(20):2449-56. [CrossRef] google scholar
Abstract
Keywords
References
- Bevan KE, Mohamed F, Moran BJ. Pseudomyxoma peritonei. World J Gastrointest Oncol 2010;2(1):44-50. [CrossRef] google scholar
- Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, Gonzâlez-Moreno S, et al. A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. Am J Surg Pathol 2016;40(1):14-26. [CrossRef] google scholar
- Shringi S Jr, Agrawal AK, Gadkari P. A Review of Pseudomyxoma Peritonei: Insights Into Diagnosis, Management, and Prognosis. Cureus 2024;16(5):e61244. [CrossRef] google scholar
- Kusamura S, Barretta F, Yonemura Y, Sugarbaker PH, Moran BJ, Levine EA, et al. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. JAMA Surg 2021;156(3):e206363. [CrossRef] google scholar
- Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012;30(20):2449-56. [CrossRef] google scholar
Details
| Primary Language | English |
|---|---|
| Subjects | Health Services and Systems (Other) |
| Journal Section | Letter |
| Authors | |
| Publication Date | October 25, 2024 |
| Submission Date | September 28, 2024 |
| Acceptance Date | October 10, 2024 |
| Published in Issue | Year 2024 Volume: 87 Issue: 4 |
Cite
Contact information and address
Addressi: İ.Ü. İstanbul Tıp Fakültesi Dekanlığı, Turgut Özal Cad. 34093 Çapa, Fatih, İstanbul, TÜRKİYE
Email: itfdergisi@istanbul.edu.tr
Phone: +90 212 414 21 61